Vitamin E Ranked First for BP—Why You Shouldn’t Take It

Vitamin E ranked first for systolic blood-pressure reduction in a 2024 network meta-analysis. The estimated difference versus placebo was a striking −14.14 mmHg. That number should prompt a better trial, not a shopping-cart decision.

The analysis compared vitamin B2, C, D, E, and folic acid in adults with essential hypertension. Vitamin E had the highest probability of ranking best for systolic blood pressure, while vitamin D landed near the bottom despite its cardiovascular-health reputation. The important distinction: a ranking estimates which treatment is most likely to lead within this particular evidence network. It does not prove that the leader reliably beats every other vitamin, or that it improves cardiovascular outcomes.

Vitamin E won the ranking, not a clinical recommendation

In the 2024 Qi et al. network meta-analysis, vitamin E produced a network-estimated systolic blood-pressure difference of −14.14 mmHg versus placebo and the highest SUCRA ranking. SUCRA is a statistical ranking tool: it estimates the probability that an intervention is the best among the treatments compared. It is useful for generating hypotheses, especially when direct head-to-head trials are scarce.

It cannot turn a patchwork of small trials into proof of superiority. The authors specifically reported small constituent samples and substantial heterogeneity. In that setting, an extreme estimate can reflect differences among trial populations, doses, study methods, baseline blood pressure, or simple chance. A high rank also does not establish that vitamin E's uncertainty interval excludes those of vitamin C, folic acid, B2, or D.

The diastolic results add another reason for restraint: the ranking for diastolic blood pressure did not mirror the systolic ranking. A treatment can affect systolic and diastolic pressure by different amounts, but a dramatic systolic signal without a matching, consistent diastolic pattern makes the apparent hierarchy less persuasive. It may reflect trial-level variation rather than a repeatable antihypertensive effect.

Blood pressure is a meaningful surrogate, but the network did not establish fewer heart attacks, strokes, or deaths. Nor can short trials tell us whether any apparent reduction persists.

Why the vitamin E mechanism is plausible—and still unproven

There is a credible biological story. Oxidative stress can reduce nitric oxide availability in blood vessels, and nitric oxide helps blood vessels relax. Antioxidants such as vitamins C and E could, in theory, preserve that signaling in people with high oxidative stress. A 2025 review of nitrate, nitric oxide, and hypertension describes this oxidative-stress and endothelial-function pathway.

Mechanistic plausibility sets up a test; it does not settle one. If vitamin E helps only in selected groups with high oxidative stress, averaging small and varied studies can produce an estimate that does not apply to healthy people taking a supplement "for optimization." The existing evidence does not identify a population in which high-dose vitamin E has a confirmed favorable benefit-risk balance for blood pressure.

Reports of vitamin E-specific meta-analyses have estimated smaller systolic changes, roughly −3 to −4 mmHg in hypertensive subgroups, than the network estimate. The discrepancy remains unresolved. Small-study effects, selected populations, and the network model itself could all contribute. Without a large randomized trial designed with blood pressure as its primary endpoint, the −14.14 mmHg result remains an estimate worth investigating.

Vitamin D is the useful reality check

Vitamin D has a reasonable theoretical connection to vascular tone and renin signaling. Large randomized evidence has not translated that idea into a meaningful blood-pressure intervention for vitamin-replete adults.

A blood-pressure analysis from the randomized D-Health Trial reported a systolic difference of −1.5 mmHg, with a 95% confidence interval from −3.2 to +0.2 mmHg and p=0.09. The result was not statistically significant; the interval includes no effect. The trial infrastructure included monthly 60,000-IU vitamin D3 supplementation in Australian adults aged 60 to 84, and the treated group achieved high 25(OH)D concentrations. The linked publication reports fall outcomes in 688 participants, while the blood-pressure result came from a separate cardiovascular analysis of the same trial program.

This pattern fits other large vitamin D trials described in the literature: systolic effects around 0 to 1.5 mmHg, with non-significant results. Low vitamin D status often travels with less outdoor activity, obesity, and poorer health—each associated with higher blood pressure. That can create an observational association without proving that supplementation lowers pressure. Treat vitamin D deficiency when clinically indicated, but do not use vitamin D as a blood-pressure treatment.

Riboflavin and folic acid: an evidence gap, not a green light

Riboflavin, or vitamin B2, has a more modest and more honest result. A 2025 Cochrane review pooled three randomized trials totaling 320 participants. The estimated systolic effect was −1.94 mmHg, with a 95% confidence interval of −5.74 to +1.86 mmHg. Cochrane rated the certainty of evidence very low.

That confidence interval includes a modest benefit, no effect, and slight harm. The review does not prove B2 fails; it shows that three small trials cannot answer the question. A 2- to 3-mmHg effect could matter across a population, but this evidence cannot establish one for an individual.

Folic acid has a targeted hypothesis around the MTHFR C677T variant and one-carbon metabolism. A population-based North Indian study linked MTHFR variation, global DNA methylation patterns, and blood-pressure differences among adults aged 35 to 65. It was cross-sectional, so it cannot show that folic acid supplementation lowers blood pressure in variant carriers. Genotype can make a hypothesis more specific; it does not make it clinically proved.

Vitamin C occupied an intermediate position in the network analysis, but it lacks large dedicated blood-pressure trials comparable with the vitamin D evidence base. Neither vitamin C nor folic acid has evidence strong enough to support a blood-pressure protocol.

Safety changes the vitamin E calculation

The vitamin E result would already need confirmation. Safety makes self-experimentation harder to justify. A prior meta-analysis has reported a dose-related all-cause mortality signal at vitamin E doses of at least 400 IU per day, overlapping with doses used in some blood-pressure trials. High-dose alpha-tocopherol can also lower circulating gamma-tocopherol, a form of vitamin E with distinct biological activity.

Those concerns do not prove that every vitamin E dose harms every person. They do mean that a provisional blood-pressure benefit is not enough to justify high-dose supplementation. The upside remains uncertain; the potential downside is not hypothetical enough to ignore.

What to do instead

For blood pressure, use interventions with better evidence and a clearer clinical role: regular exercise, lower sodium intake, a DASH-style dietary pattern, weight management when appropriate, and prescribed medication when indicated. In one eight-week randomized trial in adults with obesity and nonalcoholic fatty liver disease, DASH improved systolic and diastolic pressure within the intervention group, although the between-group blood-pressure difference was not significant. That study does not establish DASH as a substitute for treatment, but it illustrates the right direction: dietary patterns change more than one biochemical knob at a time.

The vitamin ranking has real research value. It identifies vitamin E as the leading candidate for a large, well-controlled trial that measures sustained blood pressure and safety. Until that trial exists, the practical answer to "which vitamin lowers blood pressure?" is that none of these supplements has earned a place beside established hypertension care.